Is SLP or PSNL more profitable?

Simulations Plus has a net margin of 9.88% compared to Personalis' net margin of -153.84%. Simulations Plus' return on equity of 13.50% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% Personalis -153.84% -46.47% -35.30%

Does the media prefer SLP or PSNL?

In the previous week, Personalis had 2 more articles in the media than Simulations Plus. MarketBeat recorded 6 mentions for Personalis and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Personalis' score of -0.44 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, SLP or AZTA?

Azenta has higher revenue and earnings than Simulations Plus. Azenta is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Simulations Plus $82.06M 4.52 -$64.72M $0.40 45.88 Azenta $613.81M 2.50 -$55.76M -$2.76 N/A

Is SLP or AZTA more profitable?

Simulations Plus has a net margin of 9.88% compared to Azenta's net margin of -20.63%. Simulations Plus' return on equity of 13.50% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% Azenta -20.63% 1.18% 0.97%

Does the media prefer SLP or AZTA?

In the previous week, Azenta had 18 more articles in the media than Simulations Plus. MarketBeat recorded 22 mentions for Azenta and 4 mentions for Simulations Plus. Azenta's average media sentiment score of 1.02 beat Simulations Plus' score of 0.50 indicating that Azenta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SLP or CYRX?

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Simulations Plus $82.06M 4.52 -$64.72M $0.40 45.88 CryoPort $176.18M 4.26 $78.30M -$0.90 N/A

Does the media refer more to SLP or CYRX?

In the previous week, CryoPort had 10 more articles in the media than Simulations Plus. MarketBeat recorded 14 mentions for CryoPort and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat CryoPort's score of 0.27 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, EVO or SLP?

Simulations Plus has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.83 -$117.12M N/A N/A Simulations Plus $82.06M 4.52 -$64.72M $0.40 45.88

Is EVO or SLP more profitable?

Simulations Plus has a net margin of 9.88% compared to Evotec's net margin of -26.20%. Simulations Plus' return on equity of 13.50% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Simulations Plus 9.88% 13.50% 12.45%

Does the media prefer EVO or SLP?

In the previous week, Evotec had 4 more articles in the media than Simulations Plus. MarketBeat recorded 8 mentions for Evotec and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Evotec's score of 0.02 indicating that Simulations Plus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLP or DNA?

In the previous week, Ginkgo Bioworks had 6 more articles in the media than Simulations Plus. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Ginkgo Bioworks' score of 0.37 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Simulations Plus (SLP) Competitors

$18.35 +0.03 (+0.16%)

As of 04:00 PM Eastern

Compare

SLP vs. PSNL, AZTA, CYRX, EVO, and DNA

Should you buy Simulations Plus stock or one of its competitors? MarketBeat compares Simulations Plus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Simulations Plus include Personalis (PSNL), Azenta (AZTA), CryoPort (CYRX), Evotec (EVO), and Ginkgo Bioworks (DNA). These companies are all part of the "life sciences tools & services" industry.

How does Simulations Plus compare to Personalis?

Simulations Plus (NASDAQ:SLP) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Simulations Plus has a net margin of 9.88% compared to Personalis' net margin of -153.84%. Simulations Plus' return on equity of 13.50% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Personalis	-153.84%	-46.47%	-35.30%

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by company insiders. Comparatively, 4.2% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Simulations Plus has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.52	-$64.72M	$0.40	45.88
Personalis	$69.65M	21.80	-$81.27M	-$1.09	N/A

In the previous week, Personalis had 2 more articles in the media than Simulations Plus. MarketBeat recorded 6 mentions for Personalis and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Personalis' score of -0.44 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Simulations Plus presently has a consensus target price of $17.25, indicating a potential downside of 5.99%. Personalis has a consensus target price of $14.25, indicating a potential downside of 1.72%. Given Personalis' stronger consensus rating and higher possible upside, analysts plainly believe Personalis is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Simulations Plus has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Personalis has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market.

Summary

Simulations Plus beats Personalis on 10 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to Azenta?

Simulations Plus (NASDAQ:SLP) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Simulations Plus pays an annual dividend of $0.24 per share and has a dividend yield of 1.3%. Azenta pays an annual dividend of $0.10 per share and has a dividend yield of 0.3%. Simulations Plus pays out 60.0% of its earnings in the form of a dividend. Azenta pays out -3.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Simulations Plus has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Azenta has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Simulations Plus presently has a consensus target price of $17.25, indicating a potential downside of 5.99%. Azenta has a consensus target price of $41.20, indicating a potential upside of 23.61%. Given Azenta's stronger consensus rating and higher possible upside, analysts plainly believe Azenta is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Azenta has higher revenue and earnings than Simulations Plus. Azenta is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.52	-$64.72M	$0.40	45.88
Azenta	$613.81M	2.50	-$55.76M	-$2.76	N/A

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by insiders. Comparatively, 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Simulations Plus has a net margin of 9.88% compared to Azenta's net margin of -20.63%. Simulations Plus' return on equity of 13.50% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Azenta	-20.63%	1.18%	0.97%

In the previous week, Azenta had 18 more articles in the media than Simulations Plus. MarketBeat recorded 22 mentions for Azenta and 4 mentions for Simulations Plus. Azenta's average media sentiment score of 1.02 beat Simulations Plus' score of 0.50 indicating that Azenta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Azenta beats Simulations Plus on 10 of the 18 factors compared between the two stocks.

How does Simulations Plus compare to CryoPort?

Simulations Plus (NASDAQ:SLP) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.52	-$64.72M	$0.40	45.88
CryoPort	$176.18M	4.26	$78.30M	-$0.90	N/A

Simulations Plus has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Simulations Plus has a net margin of 9.88% compared to CryoPort's net margin of -20.05%. Simulations Plus' return on equity of 13.50% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
CryoPort	-20.05%	-7.20%	-4.30%

Simulations Plus currently has a consensus price target of $17.25, suggesting a potential downside of 5.99%. CryoPort has a consensus price target of $18.00, suggesting a potential upside of 21.46%. Given CryoPort's stronger consensus rating and higher possible upside, analysts plainly believe CryoPort is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, CryoPort had 10 more articles in the media than Simulations Plus. MarketBeat recorded 14 mentions for CryoPort and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat CryoPort's score of 0.27 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Simulations Plus and CryoPort tied by winning 8 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to Evotec?

Evotec (NASDAQ:EVO) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Simulations Plus has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.83	-$117.12M	N/A	N/A
Simulations Plus	$82.06M	4.52	-$64.72M	$0.40	45.88

Evotec currently has a consensus target price of $3.00, indicating a potential upside of 44.23%. Simulations Plus has a consensus target price of $17.25, indicating a potential downside of 5.99%. Given Evotec's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evotec is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Simulations Plus has a net margin of 9.88% compared to Evotec's net margin of -26.20%. Simulations Plus' return on equity of 13.50% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Simulations Plus	9.88%	13.50%	12.45%

In the previous week, Evotec had 4 more articles in the media than Simulations Plus. MarketBeat recorded 8 mentions for Evotec and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Evotec's score of 0.02 indicating that Simulations Plus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.8% of Evotec shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 19.1% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evotec has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Summary

Simulations Plus beats Evotec on 8 of the 14 factors compared between the two stocks.

How does Simulations Plus compare to Ginkgo Bioworks?

Simulations Plus (NASDAQ:SLP) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Simulations Plus has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.52	-$64.72M	$0.40	45.88
Ginkgo Bioworks	$170.15M	2.94	-$312.76M	-$5.01	N/A

In the previous week, Ginkgo Bioworks had 6 more articles in the media than Simulations Plus. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 4 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.50 beat Ginkgo Bioworks' score of 0.37 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Simulations Plus has a net margin of 9.88% compared to Ginkgo Bioworks' net margin of -259.96%. Simulations Plus' return on equity of 13.50% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 19.1% of Simulations Plus shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Simulations Plus has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

Simulations Plus currently has a consensus target price of $17.25, suggesting a potential downside of 5.99%. Ginkgo Bioworks has a consensus target price of $7.00, suggesting a potential downside of 8.62%. Given Simulations Plus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Simulations Plus is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Summary

Simulations Plus beats Ginkgo Bioworks on 11 of the 15 factors compared between the two stocks.

Get Simulations Plus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLP vs. The Competition

Export

Metric	Simulations Plus	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$371.13M	$9.58B	$7.06B	$12.95B
Dividend Yield	N/A	1.45%	2.58%	10.20%
P/E Ratio	45.88	62.58	269.75	24.73
Price / Sales	4.52	104.71	652.34	108.63
Price / Cash	12.80	26.16	28.89	37.44
Price / Book	2.96	5.15	11.27	6.42
Net Income	-$64.72M	$56.66B	$3.45B	$347.12M
7 Day Performance	0.22%	3.54%	3.56%	2.48%
1 Month Performance	0.60%	0.51%	-0.58%	-1.04%
1 Year Performance	29.50%	23.97%	77.52%	23.22%

Simulations Plus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLP Simulations Plus	1.0756 of 5 stars	$18.35 +0.2%	$17.25 -6.0%	+29.3%	$371.13M	$82.06M	45.88	160
PSNL Personalis	1.5192 of 5 stars	$13.48 +2.1%	$14.25 +5.7%	+214.0%	$1.41B	$69.65M	N/A	400	Earnings Report
AZTA Azenta	3.2434 of 5 stars	$29.88 0.0%	$40.40 +35.2%	+10.4%	$1.37B	$593.82M	N/A	3,000	Positive News Earnings Report
CYRX CryoPort	3.1262 of 5 stars	$15.39 -0.7%	$16.38 +6.4%	+100.0%	$775.15M	$176.18M	11.39	1,186	Earnings Report Analyst Forecast
EVO Evotec	3.7173 of 5 stars	$1.94 -0.3%	$3.00 +55.0%	-49.1%	$688.40M	$891.97M	N/A	4,553	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLP) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Simulations Plus (SLP) Competitors

SLP vs. PSNL, AZTA, CYRX, EVO, and DNA

How does Simulations Plus compare to Personalis?

Summary

How does Simulations Plus compare to Azenta?

Summary

How does Simulations Plus compare to CryoPort?

Summary

How does Simulations Plus compare to Evotec?

Summary

How does Simulations Plus compare to Ginkgo Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Simulations Plus (SLP) Competitors

SLP vs. PSNL, AZTA, CYRX, EVO, and DNA

How does Simulations Plus compare to Personalis?

Is SLP or PSNL more profitable?

Do insiders and institutionals have more ownership in SLP or PSNL?

Which has better valuation and earnings, SLP or PSNL?

Does the media prefer SLP or PSNL?

Do analysts rate SLP or PSNL?

Which has more volatility & risk, SLP or PSNL?

Summary

How does Simulations Plus compare to Azenta?

Is SLP or AZTA a better dividend stock?

Which has more risk & volatility, SLP or AZTA?

Do analysts rate SLP or AZTA?

Which has better earnings & valuation, SLP or AZTA?

Do institutionals & insiders believe in SLP or AZTA?

Is SLP or AZTA more profitable?

Does the media prefer SLP or AZTA?

Summary

How does Simulations Plus compare to CryoPort?

Which has higher earnings & valuation, SLP or CYRX?

Which has more volatility & risk, SLP or CYRX?

Do insiders and institutionals hold more shares of SLP or CYRX?

Is SLP or CYRX more profitable?

Do analysts rate SLP or CYRX?

Does the media refer more to SLP or CYRX?

Summary

How does Simulations Plus compare to Evotec?

Which has preferable valuation and earnings, EVO or SLP?

Do analysts recommend EVO or SLP?

Is EVO or SLP more profitable?

Does the media prefer EVO or SLP?

Do institutionals and insiders have more ownership in EVO or SLP?

Which has more volatility and risk, EVO or SLP?

Summary

How does Simulations Plus compare to Ginkgo Bioworks?

Which has stronger earnings & valuation, SLP or DNA?

Does the media prefer SLP or DNA?

Is SLP or DNA more profitable?

Do insiders & institutionals hold more shares of SLP or DNA?

Which has more volatility and risk, SLP or DNA?

Do analysts rate SLP or DNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools